- Trials with a EudraCT protocol (574)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
574 result(s) found for: MASS syndrome.
Displaying page 7 of 29.
EudraCT Number: 2014-005526-35 | Sponsor Protocol Number: 990 | Start Date*: 2015-09-12 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated dose, Multicentre Phase IIa Proof-of-Concept Study with BT063 in Subjects with Systemic Lupus Erythematosus (BT063 in SLE) | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004776-35 | Sponsor Protocol Number: 260576 | Start Date*: 2014-04-17 | |||||||||||||||||||||
Sponsor Name:Radboud University Medical Centre Nijmegen | |||||||||||||||||||||||
Full Title: Cross-sectional study of 24-hour ambulatory blood pressure measurements and left ventricular mass using echocardiograms in late adolescents and adults with ADHD (ADDUCE protocol WP8 (cardiovascular)) | |||||||||||||||||||||||
Medical condition: Cardiovascular functioning in Attention deficit hyperactivity disorder following 3 years of treatment with methylphenidate | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004243-92 | Sponsor Protocol Number: JZP110-405 | Start Date*: 2021-06-18 | |||||||||||
Sponsor Name:Jazz Pharmaceuticals, Inc. | |||||||||||||
Full Title: Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter S... | |||||||||||||
Medical condition: Impaired cognitive function in patients with excessive daytime sleepiness associated with obstructive sleep apnea | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003643-31 | Sponsor Protocol Number: rg_13-022 | Start Date*: 2014-01-22 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Assessing the therapeutic efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension (IIH). | |||||||||||||
Medical condition: Idiopathic Intracranial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004176-18 | Sponsor Protocol Number: CHK01-02 | Start Date*: 2021-06-21 |
Sponsor Name:Chinook Therapeutics U.S., Inc. | ||
Full Title: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) | ||
Medical condition: Proteinuric glomerular diseases, including: Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g) Focal segmental glomerulosclerosis (FSGS) Alport Syndrome Diabetes kidney disease (DKD) (... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003748-22 | Sponsor Protocol Number: MRG106-11-203 | Start Date*: 2019-08-29 | |||||||||||
Sponsor Name:miRagen Therapeutics, Inc. | |||||||||||||
Full Title: PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Myc... | |||||||||||||
Medical condition: Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004326-16 | Sponsor Protocol Number: FARM93J3CJ | Start Date*: 2012-09-20 |
Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA | ||
Full Title: A Prospective Randomized study to Optimize Prednisone therapy for relapses of Idiopathic NEphrotic syndrome in children (PROPINE study) | ||
Medical condition: At least one relapse of INS in the last year, normal renal function (creatinine clearance> 90 mL/min/1.73 m2); INS in remission at the time of enrollment (if the patient has recently had a relaps... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001690-28 | Sponsor Protocol Number: 22978379 | Start Date*: 2007-09-12 | |||||||||||
Sponsor Name:Dept of Endocrinology, Odense University Hospital | |||||||||||||
Full Title: Odense Androgen Study - The effect of Testim vs strength training i a populationbased, randomised, placebocontrolled, doubleblinded study in hypogonadal men | |||||||||||||
Medical condition: This study will prodvide information on the Metabolic syndrome and the relationship with hypogonadism in older men. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024005-13 | Sponsor Protocol Number: 3098009 | Start Date*: 2011-03-11 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to syste... | |||||||||||||
Medical condition: Raynaud's phenomenon secondary to systemic sclerosis (Raynaud's syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005389-51 | Sponsor Protocol Number: RB15.210 | Start Date*: 2017-10-06 | |||||||||||
Sponsor Name:CHRU DE BREST | |||||||||||||
Full Title: Safety and Efficacy of tocilizuMAb versus placebo in Polymyalgia rHeumatica with glucocORticoid dEpendence SEMAPHORE | |||||||||||||
Medical condition: Polymyalgia rHeumatica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000818-29 | Sponsor Protocol Number: MCP-103-403 | Start Date*: 2016-08-08 | |||||||||||
Sponsor Name:Ironwood Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrom... | |||||||||||||
Medical condition: Irritable Bowel Syndrome with Constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003025-10 | Sponsor Protocol Number: VIVID | Start Date*: 2011-11-08 | |||||||||||||||||||||
Sponsor Name:King's College London [...] | |||||||||||||||||||||||
Full Title: Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease. | |||||||||||||||||||||||
Medical condition: Left ventricular hypertrophy, type 2 diabetes, chronic kidney disease. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004597-65 | Sponsor Protocol Number: RM-493-037 | Start Date*: 2022-10-20 | |||||||||||||||||||||
Sponsor Name:Rhythm Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) with a Crossover to Open-Label Once Weekly Setmelanotide in Patients with Specific Gene Defects in ... | |||||||||||||||||||||||
Medical condition: Treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Diseases that are the result of genetic defects affecting the MC4R pathway, con... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003711-60 | Sponsor Protocol Number: ALXN1840-WD-205 | Start Date*: 2021-01-15 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 2, single-arm, pathologist-blinded study using liver biopsy specimens to assess copper concentration and histopathologic changes in patients with Wilson disease who are treated with ALXN184... | |||||||||||||
Medical condition: Wilson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002704-27 | Sponsor Protocol Number: VBP15-004-A4 | Start Date*: 2019-07-06 | |||||||||||
Sponsor Name:ReveraGen BioPharma, Inc. | |||||||||||||
Full Title: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne... | |||||||||||||
Medical condition: Duchenne muscular dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) NL (Completed) CZ (Completed) GR (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004163-39 | Sponsor Protocol Number: HSJD-LIT-05 | Start Date*: 2005-11-14 |
Sponsor Name:Hospital Sant Joan de Déu | ||
Full Title: Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism ... | ||
Medical condition: Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat exces... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005013-11 | Sponsor Protocol Number: D2452L00007 | Start Date*: 2005-02-01 |
Sponsor Name:Umeå University Hospital | ||
Full Title: A 36 wk three-center double-blind randomized three-way cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo. The MEDICA study Mechanisms for the diabetes-p... | ||
Medical condition: The "metabolic syndrome" is a cluster of metabolic and cardiovascular risk factors. Insulin resistance appears to be a central disease mechanism and hypertension is another important component. A t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019643-19 | Sponsor Protocol Number: 3/19/2010 | Start Date*: 2011-01-13 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I, Abt.f.Hämatologie u.Hämostaseologie | ||
Full Title: The effect of clopidogrel and prasugrel with and without acetylsalicylic acid (ASA) on hemostatic system activation at the site of plug formation in vivo in man | ||
Medical condition: coronary artery disease and acute coronary syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002341-30 | Sponsor Protocol Number: 1705-VLC-030-JG | Start Date*: 2017-09-11 | |||||||||||
Sponsor Name:INSTITUTO VALENCIANO DE INFERTILIDAD (IVI) | |||||||||||||
Full Title: Usefulness of medroxyprogesterone acetate in the follicular phase for ovarian donors to prevent premature luteinization | |||||||||||||
Medical condition: prevent premature luteinitation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011106-42 | Sponsor Protocol Number: 2008MZ09B | Start Date*: 2009-06-25 |
Sponsor Name:Institute for Clinical and Experimental Medicine | ||
Full Title: Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus | ||
Medical condition: The project deals with hummoral and metabolic aspects of insulin resistance (IR), which is assumed to be the basic metabolic disorder which leads to the development of type 2 diabetes mellitus (T2D... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
